(Q34572999)

3 August 2017

1 reference

title

Could agomelatine be the ideal antidepressant? (English)

1 reference

Seithikurippu R. Pandi-Perumal

3 August 2017

1

object named as

S R Pandi-Perumal

1 reference

3 August 2017

Venkatramanujan Srinivasan

2

1 reference

PubMed ID

17144776

3 August 2017

D P Cardinali

3

1 reference

PubMed ID

17144776

3 August 2017

M J Monti

4

1 reference

3 August 2017

1 November 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

3 August 2017

1 reference

3 August 2017

6

1 reference

3 August 2017

11

1 reference

3 August 2017

1595-1608

1 reference

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

3 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Epidemiology and relative toxicity of antidepressant drugs in overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Selective serotonin reuptake inhibitors for children and adolescents with major depression: current controversies and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Sleep disturbances in depression and the effects of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Biological rhythm disturbances in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Melatonin in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Melatonin and sleep in aging population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

The use of chronobiotics in the resynchronization of the sleep-wake cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Effects of exogenous melatonin on sleep: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Potential use of melatonin as adjunct antihypertensive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Prolonged melatonin administration decreases nocturnal blood pressure in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Chronobiotics--drugs that shift rhythms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Melatonin as a chronobiotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Melatonin, immune function and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Functional MT1 and MT2 melatonin receptors in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Morning or night-time melatonin is ineffective in seasonal affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Sleep disturbances and depression: a challenge for antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Novel naphthalenic ligands with high affinity for the melatonin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Efficacy and tolerance profile of agomelatine and practical use in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Chronic exposure to melatonin receptor agonists does not alter their effects on suprachiasmatic nucleus neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

S20098 affects the free-running rhythms of body temperature and activity and decreases light-induced phase delays of circadian rhythms of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Melatonin analogues as agonists and antagonists in the circadian system and other brain areas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Effect of agomelatine in the chronic mild stress model of depression in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Antidepressant action of agomelatine (S 20098) in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Behavioural despair in rats: A new model sensitive to antidepressant treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Melatonin as an anxiolytic in rats: time dependence and interaction with the central GABAergic system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Distribution of the 5-hydroxytryptamine2C receptor protein in adult rat brain and spinal cord determined using a receptor-directed antibody: effect of 5,7-dihydroxytryptamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Anxiolytic-like actions of melatonin, 5-metoxytryptophol, 5-hydroxytryptophol and benzodiazepines on a conflict procedure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Melatonin reverses pinealectomy-induced decrease of benzodiazepine binding in rat cerebral cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Melatonin increases in vivo GABA accumulation in rat hypothalamus, cerebellum, cerebral cortex and pineal gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Hippocampal volume reduction in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Course of illness, hippocampal function, and hippocampal volume in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Neuroimaging studies of mood disorder effects on the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Remodeling of neuronal networks by stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Neurogenesis in the adult human hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

A neurotrophic model for stress-related mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Clinical efficacy of agomelatine in depression: the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Comparison between eye movement latency and REM sleep parameters in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

How is good and poor sleep in older adults and college students related to daytime sleepiness, fatigue, and ability to concentrate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64-99 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Chronic insomnia and immune functioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

The contribution of pain, reported sleep quality, and depressive symptoms to fatigue in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Does melatonin play a disease-promoting role in rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Effects of SSRIs on sexual function: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Efficacy of SSRIs and Newer Antidepressants in Severe Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Circadian rhythm mechanisms in affective illness and in antidepressant drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

Melatonin in Circadian Rhythm Sleep Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1595

10.1586/14737175.6.11.1595

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

17144776